Eli Lilly’s Zepbound and Mounjaro Now Available in U.S. After Shortages, FDA Says

All doses of Eli Lilly’s highly popular weight loss injection Zepbound and diabetes drug Mounjaro are now available in the U.S., according to the latest update on the U.S. Food and Drug Administration’s (FDA) drug shortage database. This follows a period where some doses of these treatments were still in short supply.

Some doses of Mounjaro have been in shortage since early 2022, while Zepbound joined the FDA’s shortage list earlier this year following its U.S. approval in November. The surge in demand for weight loss and diabetes medications has significantly outpaced supply, prompting Eli Lilly and its competitor Novo Nordisk to invest billions in ramping up manufacturing capacities.

The FDA’s update was issued just one day after Eli Lilly CEO David Ricks indicated in an interview with Bloomberg that the shortages of Mounjaro and Zepbound would end “very soon.” “I think actually today or tomorrow we plan to exit that process,” Ricks stated.

The resolution of these shortages is expected to be a significant relief for patients who rely on these medications for managing their weight and diabetes. Both Zepbound and Mounjaro have garnered substantial attention for their efficacy, contributing to the heightened demand.